Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Sigma, AB Sciex Sign Deal

By Drug Discovery Trends Editor | September 10, 2012

Sigma-Aldrich Corporation has signed an OEM agreement with AB Sciex, a leading company for high-end mass spectrometry instruments, to globally distribute its mass spectrometry based tagging chemistries called SCIEX iChemistry Solutions for applications in basic research and applied markets. The agreement strengthens the existing Sigma-Aldrich portfolio of reagents for mass spectrometry-based protein research, providing scientists access to the largest selection of high-quality tools for workflows to enable the study of the proteome.

“Mass spectrometry is a rapidly growing platform driving basic proteomics research, biomarker discovery and drug development. Particularly in the Asia-Pacific region, this distribution agreement will provide the research community with easy and reliable access to AB SCIEX’s unique reagents and consumables for mass spectrometry applications as part of a total chemistry solution. Furthermore, researchers can benefit from the combined technical expertise of Sigma-Aldrich and AB Sciex,” said Josef Zihlmann, VP Marketing, Sigma-Aldrich.

The collaboration also provides a basis for future joint development of mass spectrometry consumables.

“Sigma-Aldrich is actively expanding its portfolio of robust tools for proteomics research. In addition to establishing a complete toolset for mass spectrometry research with AB Sciex, we are continually adding to our collection of 60,000 antibodies that enable researchers to accurately discern dynamic states of proteins in key pathways throughout the proteome,” said Zihlmann.

Date: September 6, 2012
Source: Sigma-Aldrich Corporation


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50